Análisis de la acción HeartSciences Inc (HSCS)

Análisis de IA of HeartSciences Inc (HSCS)

Mantener

Heart Test Laboratories Inc (HSCS) is currently not a strong buy due to its recent performance and financial instability. The stock is priced at $2.83, which is significantly below its 52-week high of $5.25, indicating a 46.5% drop from its peak. Additionally, the RSI is at 38.7, suggesting that the stock is nearing oversold territory but still lacks strong upward momentum. The company reported a gross margin of 59.06% in Q2 2026, which is positive, but it also posted a net income loss of $2.35 million in the same quarter. The primary risk is the ongoing financial losses, with a projected EPS of -0.86 for Q4 2026, indicating continued negative earnings performance. Therefore, while there are some positive indicators, the overall financial health and recent stock performance suggest holding rather than buying at this time.

Métricas de valoración

El PER previsto actual de HeartSciences Inc (HSCS) es 0.00, frente a su media de 5 años de -1.19.

PER previsto

Sobrevalorado

Media 5A P/E

-1.19

P/E actual

0.00

Sobrevalorada

-0.26

Infravalorada

-2.13

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

1.14

EV/EBITDA actual

0.00

Sobrevalorada

6.38

Infravalorada

-4.10

Precio/ventas previsto

Valor razonable

Media 5A P/S

180.61

P/S actual

4.21

Sobrevalorada

1071.23

Infravalorada

-710.01

Escenarios de precio de Alphio AI para HSCS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%HSCS

$5.42

Precio del escenario

B

Base

Base · 50%HSCS

$4.73

Precio del escenario

B

Bajista

Bajista · 25%HSCS

$4.32

Precio del escenario

Preguntas frecuentes sobre HSCS, respondidas por Alphio AI

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Heart Test Laboratories Inc (HSCS) is currently not a strong buy due to its recent performance and financial instability. The stock is priced at $2.83, which is significantly below its 52-week high of $5.25, indicating a 46.5% drop from its peak. Additionally, the RSI is at 38.7, suggesting that the stock is nearing oversold territory but still lacks strong upward momentum. The company reported a gross margin of 59.06% in Q2 2026, which is positive, but it also posted a net income loss of $2.35 million in the same quarter. The primary risk is the ongoing financial losses, with a projected EPS of -0.86 for Q4 2026, indicating continued negative earnings performance. Therefore, while there are some positive indicators, the overall financial health and recent stock performance suggest holding rather than buying at this time.